Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$18.24 +4.8%	$19.92	$13.53 ▼ $35.25	$1.83B	2.35	1.43 million shs	2.23 million shs
IMCR Immunocore	$29.54 +4.0%	$28.80	$23.15 ▼ $59.82	$1.48B	0.75	428,264 shs	283,716 shs
IMVT Immunovant	$14.55 +3.8%	$16.38	$12.72 ▼ $34.47	$2.47B	0.75	1.21 million shs	1.05 million shs
RVMD Revolution Medicines	$41.88 +3.6%	$37.40	$29.17 ▼ $62.40	$7.80B	1.11	1.49 million shs	1.76 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+4.71%	-7.97%	+17.91%	-32.07%	-14.21%
IMCR Immunocore	+4.01%	-3.56%	+11.09%	+4.75%	-49.89%
IMVT Immunovant	+3.78%	-4.40%	-0.89%	-24.77%	-50.49%
RVMD Revolution Medicines	+3.20%	+5.25%	+17.25%	+1.04%	+12.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.839 of 5 stars	4.5	1.0	0.0	1.7	2.5	0.6
IMCR Immunocore	3.2146 of 5 stars	4.3	1.0	0.0	3.5	4.2	0.0
IMVT Immunovant	2.3054 of 5 stars	4.5	0.0	0.0	3.2	1.7	0.0
RVMD Revolution Medicines	4.3772 of 5 stars	4.5	0.0	4.7	4.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	167.27% Upside
IMCR Immunocore	2.50	Moderate Buy	$58.13	96.77% Upside
IMVT Immunovant	2.90	Moderate Buy	$38.33	163.46% Upside
RVMD Revolution Medicines	3.00	Buy	$67.17	60.38% Upside

Current Analyst Ratings Breakdown

Latest IMVT, IMCR, BEAM, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	IMCR Immunocore	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$85.00 ➝ $86.00
5/8/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
5/8/2025	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $75.00
5/8/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$87.00 ➝ $80.00
5/8/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00 ➝ $57.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
4/28/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$67.00 ➝ $67.00
4/22/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$38.00 ➝ $17.00
4/14/2025	IMCR Immunocore	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$54.00 ➝ $50.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.58M	28.85	N/A	N/A	$12.04 per share	1.51
IMCR Immunocore	$310.20M	4.77	N/A	N/A	$7.42 per share	3.98
IMVT Immunovant	N/A	N/A	N/A	N/A	$2.08 per share	N/A
RVMD Revolution Medicines	$742K	10,513.01	N/A	N/A	$11.09 per share	3.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$132.53M	-$4.61	N/A	N/A	N/A	-41.07%	-16.22%	-10.94%	N/A
IMCR Immunocore	-$55.29M	-$0.43	N/A	N/A	N/A	-15.87%	-12.84%	-5.09%	N/A
IMVT Immunovant	-$259.34M	-$2.62	N/A	N/A	N/A	N/A	-77.94%	-69.82%	6/4/2025 (Estimated)
RVMD Revolution Medicines	-$436.37M	-$4.00	N/A	N/A	N/A	N/A	-33.67%	-30.08%	N/A

Latest IMVT, IMCR, BEAM, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/4/2025	Q4 2025	IMVT Immunovant	-$0.72	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	IMCR Immunocore	-$0.35	$0.10	+$0.45	$0.10	$108.82 million	$125.13 million
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
2/26/2025	Q4 2024	RVMD Revolution Medicines	-$1.01	-$1.12	-$0.11	-$1.12	$0.35 million	N/A
2/25/2025	Q4 2024	BEAM Beam Therapeutics	-$1.25	-$1.09	+$0.16	-$1.09	$16.47 million	$30.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	4.93%	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	5.69	5.69
IMCR Immunocore	1.03	3.78	3.76
IMVT Immunovant	N/A	6.04	6.04
RVMD Revolution Medicines	N/A	14.24	14.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
IMCR Immunocore	84.50%
IMVT Immunovant	47.08%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	4.20%
IMCR Immunocore	10.40%
IMVT Immunovant	5.90%
RVMD Revolution Medicines	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	79.33 million	Optionable
IMCR Immunocore	320	50.07 million	45.48 million	Optionable
IMVT Immunovant	120	169.86 million	159.84 million	Optionable
RVMD Revolution Medicines	250	186.26 million	154.76 million	Optionable

IMVT, IMCR, BEAM, and RVMD Headlines

Recent News About These Companies

Research Analysts Issue Forecasts for RVMD FY2025 Earnings

May 13 at 3:11 AM | americanbankingnews.com

Leerink Partnrs Has Positive Outlook of RVMD FY2025 Earnings

May 13 at 2:56 AM | marketbeat.com

Wedbush Expects Reduced Earnings for Revolution Medicines

May 13 at 1:31 AM | marketbeat.com

Fred Alger Management LLC Sells 392,547 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

May 12 at 5:35 AM | marketbeat.com

Ameriprise Financial Inc. Acquires 141,426 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

May 12 at 4:15 AM | marketbeat.com

Farallon Capital Management LLC Boosts Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 11 at 7:39 AM | marketbeat.com

Algert Global LLC Buys 6,925 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

May 11 at 4:57 AM | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Stake Boosted by Schonfeld Strategic Advisors LLC

May 11 at 4:41 AM | marketbeat.com

Revolution Medicines' (RVMD) "Buy" Rating Reiterated at Needham & Company LLC

May 11 at 1:39 AM | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Given "Buy" Rating at Needham & Company LLC

May 10 at 8:06 AM | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) is DAFNA Capital Management LLC's 3rd Largest Position

May 10 at 7:30 AM | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) is Deerfield Management Company L.P. Series C's 7th Largest Position

May 10 at 7:26 AM | marketbeat.com

Dimensional Fund Advisors LP Sells 6,698 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

May 10 at 3:45 AM | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Shares Gap Up on Analyst Upgrade

May 10 at 1:05 AM | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Brevan Howard Capital Management LP

May 9, 2025 | marketbeat.com

Northern Trust Corp Has $67.36 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 9, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Rating of "Buy" from Brokerages

May 9, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Holdings Cut by Casdin Capital LLC

May 8, 2025 | marketbeat.com

Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript

May 7, 2025 | seekingalpha.com

Revolution Medicines, Inc. 2025 Q1 - Results - Earnings Call Presentation

May 7, 2025 | seekingalpha.com

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

May 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT, IMCR, BEAM, and RVMD Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$18.24 +0.83 (+4.77%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$18.70 +0.46 (+2.52%)

As of 04:16 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Immunocore NASDAQ:IMCR

$29.54 +1.14 (+4.01%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$29.53 -0.01 (-0.03%)

As of 04:04 AM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Immunovant NASDAQ:IMVT

$14.55 +0.53 (+3.78%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$14.41 -0.14 (-0.96%)

As of 04:10 AM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Revolution Medicines NASDAQ:RVMD

$41.88 +1.46 (+3.61%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$39.66 -2.22 (-5.29%)

As of 04:16 AM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time